Momenta Phamaceuticals, Inc. (MNTA) Misses Q2 EPS by 5c

Momenta Phamaceuticals, Inc. (NASDAQ: MNTA) reported Q2 EPS of ($0.51), $0.05 worse than the analyst estimate of ($0.46). Revenue for the quarter came in at $11 million versus the consensus estimate of $11.22 million.

Financial Guidance

Today, Momenta updated its financial guidance for the second half of 2014: Momenta expects total operating expenses, excluding stock-based compensation and net of collaborative revenues, to average $28 to $30 million per quarter. Momenta is projecting that its net cash usage, excluding revenue from the potential launch of M356, will average approximately $26 million per quarter. Cash burn for the fourth quarter of 2014 is expected to be partially offset by $19 million from milestone payments earned under the Baxter collaboration, although all or a portion of these milestone payments could be received in the first quarter of 2015.

For earnings history and earnings-related data on Momenta Phamaceuticals, Inc. (MNTA) click here.

You May Also Be Interested In

• Tractor Supply (TSCO) Tops Q1 EPS by 12c ; Offers Guidance
• Grainger (GWW) Tops Q1 EPS by 2c, provides guidance
• Cullen/Frost Bankers (CFR) Misses Q1 EPS by 3c